SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

Abstract Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially non–small-cell lung cancer (NSCLC). De...

Full description

Bibliographic Details
Main Authors: Yu Chen, Min Gao, Zhaoqin Huang, Jinming Yu, Xiangjiao Meng
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Journal of Hematology & Oncology
Subjects:
Stereotactic body radiation therapy (SBRT)
PD-1/PD-L1 inhibitors
Combination treatment
Non-small-cell lung cancer (NSCLC)
Advances
Challenges
Online Access:http://link.springer.com/article/10.1186/s13045-020-00940-z

Internet

http://link.springer.com/article/10.1186/s13045-020-00940-z

Similar Items